Scientific basis for cancer prevention intermediate cancer markers

Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1993-08, Vol.72 (S3), p.978-983
Hauptverfasser: Mulshine, James L., Jett, Marti, Cuttitta, Frank, Treston, Anthony M., Quinn, Kathryn, Scott, Frank, Iwai, Noamichi, Avis, Ingalill, Ilona Linnoila, R., Shaw, Gail L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 983
container_issue S3
container_start_page 978
container_title Cancer
container_volume 72
creator Mulshine, James L.
Jett, Marti
Cuttitta, Frank
Treston, Anthony M.
Quinn, Kathryn
Scott, Frank
Iwai, Noamichi
Avis, Ingalill
Ilona Linnoila, R.
Shaw, Gail L.
description Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress in this field is a clear understanding of the complex biology of the early stages of cancerization that proceed on the epithelial surface. Systematic analysis of the biology of strategic targets such as growth factors is one approach to this problem. Gastrin‐releasing peptide is an autocrine growth factor for certain types of lung cancer cells. Mechanisms involved in the production and activation of this peptide are discussed as an example of how rational approaches to neutralization of cancer promotion biology can be achieved. The tools to monitor the success of this type of intervention also emerge from the understanding of the biology of growth factors, and intermediate end point markers that determine the presence or effects of a growth factor are attractive candidates for evaluation. Additional biologic tools reflecting the early stages of the cancer process need to be validated for use in serially evaluating the status of the relevant epithelium so that the ongoing success of a cancer intervention procedure can be established. Through this type of translational research, important applications of molecular biology may greatly improve the success of preventative strategies for cancer control.
doi_str_mv 10.1002/1097-0142(19930801)72:3+<978::AID-CNCR2820721305>3.0.CO;2-T
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75850580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75850580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4795-8a3aac20770ca741ae42fcb1cd6c459249bc8376eead999914997ecf441962063</originalsourceid><addsrcrecordid>eNqNkF2LEzEUhoMoa3f1JwhzIeIiU08-ZpJ0RVjHr4XFglYQvDik6RmITmdq0ir7783QbkEvxNyE8Lx5eXkYazhMOYB4zsHqErgST7m1Egzwcy1m8tkLq81sdnn1umw-NB-FEaAFl1C9lFOYNvMLUS7usMnx9102AQBTVkp-uc9OU_qWn1pU8oSdGClVreWEvfrkA_Xb0AZfLF0KqWiHWHjXe4rFJtLPEQ59EfotxTWtgtvSLV67-J1iesDuta5L9PBwn7HPb98smvfl9fzdVXN5XXqlbVUaJ53zebMG77TijpRo_ZL7Ve1VZYWyS2-kroncyubDlbWafKsUt7WAWp6xJ_veTRx-7ChtcR2Sp65zPQ27hLoyFVQGcvDrPujjkFKkFjcx5LE3yAFHwzg6wtER3hpGLVAiZsOI2TD-aTgjwGaOAhe5_dFhxm6ZhRy7D0ozf3zgLnnXtTHLCukYU6YSXIwx2sd-hY5u_nvhOPCf-_4i8jdPKqUc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75850580</pqid></control><display><type>article</type><title>Scientific basis for cancer prevention intermediate cancer markers</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mulshine, James L. ; Jett, Marti ; Cuttitta, Frank ; Treston, Anthony M. ; Quinn, Kathryn ; Scott, Frank ; Iwai, Noamichi ; Avis, Ingalill ; Ilona Linnoila, R. ; Shaw, Gail L.</creator><creatorcontrib>Mulshine, James L. ; Jett, Marti ; Cuttitta, Frank ; Treston, Anthony M. ; Quinn, Kathryn ; Scott, Frank ; Iwai, Noamichi ; Avis, Ingalill ; Ilona Linnoila, R. ; Shaw, Gail L.</creatorcontrib><description>Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress in this field is a clear understanding of the complex biology of the early stages of cancerization that proceed on the epithelial surface. Systematic analysis of the biology of strategic targets such as growth factors is one approach to this problem. Gastrin‐releasing peptide is an autocrine growth factor for certain types of lung cancer cells. Mechanisms involved in the production and activation of this peptide are discussed as an example of how rational approaches to neutralization of cancer promotion biology can be achieved. The tools to monitor the success of this type of intervention also emerge from the understanding of the biology of growth factors, and intermediate end point markers that determine the presence or effects of a growth factor are attractive candidates for evaluation. Additional biologic tools reflecting the early stages of the cancer process need to be validated for use in serially evaluating the status of the relevant epithelium so that the ongoing success of a cancer intervention procedure can be established. Through this type of translational research, important applications of molecular biology may greatly improve the success of preventative strategies for cancer control.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19930801)72:3+&lt;978::AID-CNCR2820721305&gt;3.0.CO;2-T</identifier><identifier>PMID: 8334673</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Anticarcinogenic Agents - chemistry ; Biological and medical sciences ; biomarker promotion biology ; Biomarkers, Tumor ; Cell Division - drug effects ; epithelium ; Gastrin-Releasing Peptide ; Host-tumor relations. Immunology. Biological markers ; Humans ; intermediate end point marker ; Lung Neoplasms - etiology ; Lung Neoplasms - pathology ; Medical sciences ; Neoplasms - prevention &amp; control ; Peptides - physiology ; Tumors</subject><ispartof>Cancer, 1993-08, Vol.72 (S3), p.978-983</ispartof><rights>Copyright © 1993 American Cancer Society</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4795-8a3aac20770ca741ae42fcb1cd6c459249bc8376eead999914997ecf441962063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23911,23912,25120,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4852123$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8334673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mulshine, James L.</creatorcontrib><creatorcontrib>Jett, Marti</creatorcontrib><creatorcontrib>Cuttitta, Frank</creatorcontrib><creatorcontrib>Treston, Anthony M.</creatorcontrib><creatorcontrib>Quinn, Kathryn</creatorcontrib><creatorcontrib>Scott, Frank</creatorcontrib><creatorcontrib>Iwai, Noamichi</creatorcontrib><creatorcontrib>Avis, Ingalill</creatorcontrib><creatorcontrib>Ilona Linnoila, R.</creatorcontrib><creatorcontrib>Shaw, Gail L.</creatorcontrib><title>Scientific basis for cancer prevention intermediate cancer markers</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress in this field is a clear understanding of the complex biology of the early stages of cancerization that proceed on the epithelial surface. Systematic analysis of the biology of strategic targets such as growth factors is one approach to this problem. Gastrin‐releasing peptide is an autocrine growth factor for certain types of lung cancer cells. Mechanisms involved in the production and activation of this peptide are discussed as an example of how rational approaches to neutralization of cancer promotion biology can be achieved. The tools to monitor the success of this type of intervention also emerge from the understanding of the biology of growth factors, and intermediate end point markers that determine the presence or effects of a growth factor are attractive candidates for evaluation. Additional biologic tools reflecting the early stages of the cancer process need to be validated for use in serially evaluating the status of the relevant epithelium so that the ongoing success of a cancer intervention procedure can be established. Through this type of translational research, important applications of molecular biology may greatly improve the success of preventative strategies for cancer control.</description><subject>Anticarcinogenic Agents - chemistry</subject><subject>Biological and medical sciences</subject><subject>biomarker promotion biology</subject><subject>Biomarkers, Tumor</subject><subject>Cell Division - drug effects</subject><subject>epithelium</subject><subject>Gastrin-Releasing Peptide</subject><subject>Host-tumor relations. Immunology. Biological markers</subject><subject>Humans</subject><subject>intermediate end point marker</subject><subject>Lung Neoplasms - etiology</subject><subject>Lung Neoplasms - pathology</subject><subject>Medical sciences</subject><subject>Neoplasms - prevention &amp; control</subject><subject>Peptides - physiology</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF2LEzEUhoMoa3f1JwhzIeIiU08-ZpJ0RVjHr4XFglYQvDik6RmITmdq0ir7783QbkEvxNyE8Lx5eXkYazhMOYB4zsHqErgST7m1Egzwcy1m8tkLq81sdnn1umw-NB-FEaAFl1C9lFOYNvMLUS7usMnx9102AQBTVkp-uc9OU_qWn1pU8oSdGClVreWEvfrkA_Xb0AZfLF0KqWiHWHjXe4rFJtLPEQ59EfotxTWtgtvSLV67-J1iesDuta5L9PBwn7HPb98smvfl9fzdVXN5XXqlbVUaJ53zebMG77TijpRo_ZL7Ve1VZYWyS2-kroncyubDlbWafKsUt7WAWp6xJ_veTRx-7ChtcR2Sp65zPQ27hLoyFVQGcvDrPujjkFKkFjcx5LE3yAFHwzg6wtER3hpGLVAiZsOI2TD-aTgjwGaOAhe5_dFhxm6ZhRy7D0ozf3zgLnnXtTHLCukYU6YSXIwx2sd-hY5u_nvhOPCf-_4i8jdPKqUc</recordid><startdate>19930801</startdate><enddate>19930801</enddate><creator>Mulshine, James L.</creator><creator>Jett, Marti</creator><creator>Cuttitta, Frank</creator><creator>Treston, Anthony M.</creator><creator>Quinn, Kathryn</creator><creator>Scott, Frank</creator><creator>Iwai, Noamichi</creator><creator>Avis, Ingalill</creator><creator>Ilona Linnoila, R.</creator><creator>Shaw, Gail L.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930801</creationdate><title>Scientific basis for cancer prevention intermediate cancer markers</title><author>Mulshine, James L. ; Jett, Marti ; Cuttitta, Frank ; Treston, Anthony M. ; Quinn, Kathryn ; Scott, Frank ; Iwai, Noamichi ; Avis, Ingalill ; Ilona Linnoila, R. ; Shaw, Gail L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4795-8a3aac20770ca741ae42fcb1cd6c459249bc8376eead999914997ecf441962063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Anticarcinogenic Agents - chemistry</topic><topic>Biological and medical sciences</topic><topic>biomarker promotion biology</topic><topic>Biomarkers, Tumor</topic><topic>Cell Division - drug effects</topic><topic>epithelium</topic><topic>Gastrin-Releasing Peptide</topic><topic>Host-tumor relations. Immunology. Biological markers</topic><topic>Humans</topic><topic>intermediate end point marker</topic><topic>Lung Neoplasms - etiology</topic><topic>Lung Neoplasms - pathology</topic><topic>Medical sciences</topic><topic>Neoplasms - prevention &amp; control</topic><topic>Peptides - physiology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mulshine, James L.</creatorcontrib><creatorcontrib>Jett, Marti</creatorcontrib><creatorcontrib>Cuttitta, Frank</creatorcontrib><creatorcontrib>Treston, Anthony M.</creatorcontrib><creatorcontrib>Quinn, Kathryn</creatorcontrib><creatorcontrib>Scott, Frank</creatorcontrib><creatorcontrib>Iwai, Noamichi</creatorcontrib><creatorcontrib>Avis, Ingalill</creatorcontrib><creatorcontrib>Ilona Linnoila, R.</creatorcontrib><creatorcontrib>Shaw, Gail L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mulshine, James L.</au><au>Jett, Marti</au><au>Cuttitta, Frank</au><au>Treston, Anthony M.</au><au>Quinn, Kathryn</au><au>Scott, Frank</au><au>Iwai, Noamichi</au><au>Avis, Ingalill</au><au>Ilona Linnoila, R.</au><au>Shaw, Gail L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scientific basis for cancer prevention intermediate cancer markers</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-08-01</date><risdate>1993</risdate><volume>72</volume><issue>S3</issue><spage>978</spage><epage>983</epage><pages>978-983</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Promising cancer clinical trials results involving the disruption of early stages of cancer with intervention agents such as tamoxifen or retinoids have led to significant new research interest in developing preventative strategy for the control of epithelial cancers. Key to the efficient progress in this field is a clear understanding of the complex biology of the early stages of cancerization that proceed on the epithelial surface. Systematic analysis of the biology of strategic targets such as growth factors is one approach to this problem. Gastrin‐releasing peptide is an autocrine growth factor for certain types of lung cancer cells. Mechanisms involved in the production and activation of this peptide are discussed as an example of how rational approaches to neutralization of cancer promotion biology can be achieved. The tools to monitor the success of this type of intervention also emerge from the understanding of the biology of growth factors, and intermediate end point markers that determine the presence or effects of a growth factor are attractive candidates for evaluation. Additional biologic tools reflecting the early stages of the cancer process need to be validated for use in serially evaluating the status of the relevant epithelium so that the ongoing success of a cancer intervention procedure can be established. Through this type of translational research, important applications of molecular biology may greatly improve the success of preventative strategies for cancer control.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8334673</pmid><doi>10.1002/1097-0142(19930801)72:3+&lt;978::AID-CNCR2820721305&gt;3.0.CO;2-T</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1993-08, Vol.72 (S3), p.978-983
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_75850580
source MEDLINE; Alma/SFX Local Collection
subjects Anticarcinogenic Agents - chemistry
Biological and medical sciences
biomarker promotion biology
Biomarkers, Tumor
Cell Division - drug effects
epithelium
Gastrin-Releasing Peptide
Host-tumor relations. Immunology. Biological markers
Humans
intermediate end point marker
Lung Neoplasms - etiology
Lung Neoplasms - pathology
Medical sciences
Neoplasms - prevention & control
Peptides - physiology
Tumors
title Scientific basis for cancer prevention intermediate cancer markers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A00%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scientific%20basis%20for%20cancer%20prevention%20intermediate%20cancer%20markers&rft.jtitle=Cancer&rft.au=Mulshine,%20James%20L.&rft.date=1993-08-01&rft.volume=72&rft.issue=S3&rft.spage=978&rft.epage=983&rft.pages=978-983&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19930801)72:3+%3C978::AID-CNCR2820721305%3E3.0.CO;2-T&rft_dat=%3Cproquest_cross%3E75850580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75850580&rft_id=info:pmid/8334673&rfr_iscdi=true